Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Engagement Labs Releases FY 2018 Audited Results, Launches Prospectus Offering of approximately $1,800,000 in Units Led by Gravitas Securities, Proposes Debt Reorganization for approval by Debentureholders and 2:1 Share Consolidation

Published

5 years ago

on

Reading Time: 5 minutes

 

Engagement Labs Inc. (TSXV: EL) (OTCQB: ELBSF) released results for its fiscal year ended December 31, 2018. Audited consolidated Financial Statements and Management Report are available on SEDAR’s website at www.sedar.com.

Fiscal Year 2018 Audited Results Released

  • TotalSocial® revenue increased by 113% from year ended December 31, 2017 to year ended December 31, 2018.
  • The number of brands using TotalSocial® increased to 20 during 2018, up from 9, and the number of industry sectors increased from 6 to 11. New sectors include Sports, Retail/Apparel, Beverage, Agency and Travel, to go along with Media, Beauty, Telecom, Software, Food and Financial.
  • Total revenue, including both TotalSocial® and the Company’s legacy products, was $3,973,704 for the year ended December 31, 2018, an increase of 15% compared to $3,469,767 for the year ended December 31, 2017.  In the US, year-over-year growth was 26%, while the UK saw a decline for the year.
  • Gross profit increased by 25%, from $1,457,485 for the year ended December 31, 2017 to $1,818,527 for the year ended December 31, 2018. As a percentage of revenue, the gross margin increased by 4%, from 42% for the year ended December 31, 2017 to 46% for the year ended December 31, 2018.
  • Non-GAAP Adjusted EBITDA loss increased by 20%, from –$2,684,152 for the year ended December 31, 2017 to –$3,228,681 for the year ended December 31, 2018. Operating expenses before extraordinary items increased by 18%, from $5,514,535 for the year ended December 31, 2017 to $6,533,005 for the year ended December 31, 2018.
  • The net loss before income taxes for the year ended December 31, 2018 increased to –$5,628,884, up 26% or –$1,170,877 from –$4,458,007 for the year ended December 31, 2017. Basic and diluted loss per share was –$0.03 for the year ended December 31, 2018, compared to –$0.05 for the year ended December 31, 2017.

Fourth Quarter Financial Highlights

  • TotalSocial® Revenue of $1,109,923 for Q4 2018 represents a 137% increase vs Q4 2017 of $467,908, and a 34% increase vs Q3 2018 of $829,739.
  • Total revenue, including both TotalSocial® and the Company’s legacy products was $1,139,156 for Q4 2018, an increase of 29% from $883,342 in Q3 2018, and an increased of 15%, from $989,553 for Q4 2017.
  • Gross margin increased to 54% in Q4 2018, from 40% in Q3 2018 and from 39% in Q4 2017.
  • Operating expenses, before extraordinary items, have increased to $1,774,244 in Q4 2018, up 21% or $301,912 from $1,472,332 in Q3 2018, and up 5% or $83,644 from $1,690,600 in Q4 2017. The increase from 2017 reflects management’s commitment to invest in sales and marketing to drive TotalSocial® technology sales growth, including the hiring of a Chief Revenue Officer in late December 2017.
  • Excluding extraordinary items and future income taxes, the net loss has increased to –$1,411,297 in Q4 2018, up 5% or –$61,745 from –$1,349,552 in Q3 2018, and down 9% or –$138,746 from –$1,550,043 in Q4 2017.
  • EBITDA loss of –$1,012,039 for Q4 2018, representing an increase of $30,190, from –$981,849 for Q3 2018, and an increase of –$465,427, from –$546,612 for Q4 2017.
  • Non-GAAP Adjusted EBITDA loss of –$735,594 for Q4 2018, representing an improvement of $11,838, from –$747,432for Q3 2018, and an improvement of $313,613, from –$1,049,207 for Q4 2017.
  • Operating expenses increased 17% or $212,074 from Q3 2017. The increase from 2017 reflects management’s commitment to invest in sales and marketing to drive TotalSocial® technology sales growth, including the hiring of a Chief Revenue Officer in late December.
  • Basic and diluted income per share was –$0.01 for Q4 2018 compared to –$0.01 for Q4 2017 and Q3 2018.
  • As at December 31, 2018, the Company had cash (excluding restricted cash) of $906,455, compared to $2,677,049as of December 31, 2017.

“I said a year ago that 2018 is shaping up to be a transformative year for Engagement Labs as TotalSocial is now resonating with clients and prospects,” said Ed Keller, CEO.  “Our year end results show the amount of progress we have made.  We grew our number of clients and our range of sectors served.”

Corporate Restructuring

Proposed Share Consolidation and Amendment to Terms of Outstanding Debentures
Engagement Labs has mailed a Notice of Special Meeting of Shareholders providing for the proposed consolidation of the common shares of the Company on a two-for-one basis effective on or about May 27, 2019.  The Meeting Materials also contemplate the approval of the issue of approximately 6,000,000 common shares on a post-consolidation basis at a price of $0.06 per share for fees owing to directors for 14 months of services for the period ended December 31, 2018.  The payment in shares is to conserve cash of Engagement Labs and is subject to approval of the TSX Venture Exchange.

Engagement Labs has mailed a Notice of Meeting and Management Information Circulars (“Meeting Materials”) to holders of the 1% Debentures, and separate Meeting Materials to 2% Debentures, both of which series are due September 28, 2020.  Engagement Labs is proposing to holders of 1% Debentures, of which there are approximately $4.23 million outstanding, and holders of 2% Debentures, of which there are approximately $1.6 million outstanding, to amend the terms of their debentures, subject to approval of 90% of the debentures outstanding of each series of debentures at a meeting or in writing, providing for the conversion of all of their outstanding debentures at a price of $0.11 per share for the 1% Debentures and $0.06 per share for the 2% Debentures, effective on or about May 27, 2019. These amendments, if approved, would cause all outstanding debentures to be cancelled and would substantially improve the Company’s financial position.  The pricing of the conversion of the debentures is subject to final approval of the TSX Venture Exchange.

Prospectus Offering 
The Company has entered into an agreement with Gravitas Securities Inc. (the “Agent”), pursuant to which the Agent has agreed to  sell on a commercially reasonable efforts basis by short form prospectus, up to 30,000,000 units of the Company (the “Units”) at a price of $0.06 per Unit for aggregate gross proceeds to the Company of up to $1,800,000. Each Unit will be comprised of one common share of the Company, one-half of one common share purchase warrant (each such whole common share purchase warrant, a “$0.10 Warrant”) and a second one-half of one common share purchase warrant (each such whole common share purchase warrant, a “$0.12 Warrant”). Each $0.10 Warrant will be exercisable into one common share at an exercise price of $0.10 per share for a period of 6 months after the Closing Date (as defined herein). Each $0.12 Warrant will be exercisable into one common share at an exercise price of $0.12 per share for a period of 2 years after the Closing Date. The offering is subject to a minimum offering amount of $1,500,000.

The Company has also agreed to grant the Agent an over-allotment option to purchase up to an additional 4,500,000 Units at the offering price, exercisable in whole or in part, for a period ending 30 days from and including the Closing Date. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $2,070,000.

The Units will be offered in each of the provinces of British Columbia, Alberta, Manitoba and Ontario by short form prospectus.

The offering is expected to close on or about May 27, 2019 (the “Closing Date”) and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange, the consolidation of the common shares of the Company on a two-for-one basis having occurred, the conversion of certain outstanding debentures of the Company in accordance with their terms and the issuance of a receipt for a final short form prospectus.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of Engagement Labs Inc. in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the United States Securities Act of 1933, as amended, and applicable state securities laws or unless an exemption from such registration is available.

 

SOURCE Engagement Labs

Related Topics:

Wladimir P. is a Content Editor at European Gaming Media and at PICANTE Media and covers a large variety of industries.

Continue Reading

Artificial Intelligence

Loyalty Juggernaut Receives US Patent for Innovative Technology Enabling Individualized Experiences at Scale

Published

1 hour ago

on

May 20, 2024

By

loyalty-juggernaut-receives-us-patent-for-innovative-technology-enabling-individualized-experiences-at-scale

3rd Patent Award Adds to Growing IP Portfolio and Reinforces Commitment to Innovation
CHICAGO, May 20, 2024 /PRNewswire/ — CRMC Show – Loyalty Juggernaut, Inc. (LJI), the loyalty industry’s first cloud-native technology platform for Loyalty Programs, Loyalty Ecosystems, and Digital Marketing, today announced at CRMC that the United States Patent and Trademark Office has awarded a patent (#11978082) for LJI’s groundbreaking use of AI. This patented technology enables brands to deliver individualized offers to program members at scale.

“This transformative feature allows a single loyalty campaign to be personalized and tailored across an entire member base, effortlessly achieving what we call ‘mass individualization,’ which is the stated mission and #1 priority of loyalty programs globally,” said Shyam Shah, CEO and Co-Founder of Loyalty Juggernaut. “This patent marks a significant milestone for us and reinforces our vision of how loyalty programs engage customers by delivering experiences that are 1:1 personalized.”
This marks the third patent for LJI, making their GRAVTY® platform the only loyalty technology globally with patents for three essential capabilities required to future-proof today’s loyalty programs and ecosystems. The other two patents are for:
1.GRAVTY Visual Rules (GVR): The only patented “no-code” rules engine in the loyalty technology industry, empowering loyalty professionals by combining extreme sophistication with extraordinary simplicity  (watch GVR in action here).
2. Multi-dimensional Behavior (1st party data) Tracking: This feature is particularly significant in today’s age of cookie-less consumers, as the reliance on high-quality first-party data grows in driving individualized customer experiences and maximizing the effectiveness of digital marketing and data-driven initiatives.
“Loyalty marketers are always looking for ways to engage customers 1:1 at scale. This innovation is groundbreaking in its use of AI to drive mass personalization, the holy grail of loyalty programs,” said Bill Hanifin, Chief Executive Officer, Wise Marketer Group.
Media Contact: [email protected]
About Loyalty Juggernaut
Headquartered in Silicon Valley, Loyalty Juggernaut, Inc. is the next-gen customer engagement and loyalty solutions enterprise helping brands transform their loyalty programs into data-led businesses to maximize customer value and compete at scale. LJI’s GRAVTY® platform powers over 40 loyalty ecosystems globally, involving 4,000+ participating brands across 12 industries including Retail, CPG, Hospitality, Airline, BFSI, Telco, and multi-brand diversified business conglomerates. Customers include Majid Al Futtaim, Liverpool, Global Hotel Alliance, Deutsche Telekom, Viva Aerobus.
#loyaltymarketing #loyaltyprograms #customerengagement #CX #individualization #personalization
Follow us on LinkedIn. More at www.lji.io
Logo: https://mma.prnewswire.com/media/2251954/4350951/Loyalty_Juggernaut_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/loyalty-juggernaut-receives-us-patent-for-innovative-technology-enabling-individualized-experiences-at-scale-302150520.html

Continue Reading

Artificial Intelligence

Vantiva Powers New Vodafone Fiber Router and Wi-Fi 6 Mesh Extender to Enhance In-Home Broadband Experience

Published

3 hours ago

on

May 20, 2024

By

CPE leverages Vantiva’s Wi-Fi antenna expertise to connect more than 100 smart devices at ultra-high speeds
PARIS, May 20, 2024 /PRNewswire/ — Vantiva (Euronext Paris: VANTI), a global technology leader enabling Network Service Providers (NSPs) to connect consumers around the world, today announced that it has strengthened its longstanding partnership with Vodafone UK, the largest full fiber provider in the UK, with the introduction of the Wi-Fi 6 enabled Power Hub router and Super Wi-Fi 6 Booster. The customer premises equipment (CPE) leverages Vantiva’s Wi-Fi antenna expertise to offer intelligent Wi-Fi auto-optimization that automatically provides the fastest connectivity across all devices. The router and booster are designed to cost-effectively deliver a superior whole-home Wi-Fi experience to end-users with the ability to seamlessly connect more than 100 smart devices at speeds up to 910 Mbps.

“The introduction of the Power Hub router and Super Wi-Fi 6 Booster are the latest examples Vodafone UK’s continued leadership in bringing advanced connectivity solutions to its customers,” said Mercedes Pastor, Senior Vice-President of the Customer Unit, Eurasia. “This is a step forward in our long-time partnership delivering cutting edge solutions in this market. The outstanding Wi-Fi performance leverages all of Vantiva’s expertise from antenna design to unique testing environments to offer the best in-home wireless experience.”
Vodafone UK’s new Power Hub router is built for fiber-to-the-home network configuration and is easily adaptable for current and future in-home connectivity demands. The Super Wi-Fi 6 Booster works seamlessly with the Power Hub to give reliable coverage throughout the home and is compatible with both existing and previous versions of Vodafone gateways. The extender’s mesh Wi-Fi capability adapts the connectivity to give customers comprehensive Wi-Fi coverage.
As part of Vantiva’s commitment to developing eco-friendly products with low-carbon intensity, the device housing for these products was made from 95% recycled plastic. The packaging was designed using 85% recycled paper, printed with soy ink and uses no plastics.
Vantiva and Vodafone UK have been collaboratively bringing innovative solutions to market in multiple product platforms since 2018 and in fiber since 2022, when the two organizations introduced the first Wi-Fi 6E gateway in the UK, bringing high speed connectivity to homes across the country. 
The Vodafone Power Hub Wi-Fi 6 router and Super Wi-Fi 6 Booster are the latest strategic milestones in Vantiva’s ongoing commitment to providing open and innovative technologies for NSPs and Pay TV operators. Vantiva’s goal is to bring seamless connectivity and premium entertainment experiences to consumers by creating best-in-class CPE and partnering with the most innovative companies in the connected home ecosystem.
Contact: Vantiva Press RelationsThatcher+Co. for [email protected]
PDF – https://mma.prnewswire.com/media/2416910/Vantiva_PDF.pdfLogo – https://mma.prnewswire.com/media/2411147/4715583/Vantiva_logo.jpg
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/vantiva-powers-new-vodafone-fiber-router-and-wi-fi-6-mesh-extender-to-enhance-in-home-broadband-experience-302150257.html

Continue Reading

Artificial Intelligence

Life Science Equipment Market to be Worth $97.96 Billion by 2031 – Exclusive Report by Meticulous Research®

Published

7 hours ago

on

May 20, 2024

By

life-science-equipment-market-to-be-worth-$97.96-billion-by-2031-–-exclusive-report-by-meticulous-research

REDDING, Calif., May 20, 2024 /PRNewswire/ — According to a new market research report titled, ‘Life Science Equipment Market Size, Share, Forecast, & Trends Analysis By Technology (Spectroscopy, Microscopy, Chromatography (HPLC, GC, TLC), PCR, Immunoassay, Sequencing, Flow Cytometry, Microarray, Centrifuge) End User – Global Forecast to 2031,’ published by Meticulous Research®, the life science equipment market is projected to reach $97.96 billion by 2031, at a CAGR of 6.3% from 2024 to 2031.

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=3937 
Life sciences encompass a wide range of fields, including biology, biochemistry, genetics, pharmacology, and many more. Laboratory equipment plays a critical role in conducting experiments, collecting data, and analyzing samples to further scientific research and advance our understanding of living organisms and their underlying mechanisms. Equipment is also necessary for quality checks and validation of manufactured drugs and biologics in the life sciences industry. The growth of the life sciences industry is driving the adoption of life sciences and laboratory equipment.
The growth of this market is attributed to several factors, including increasing pharmaceutical and biotech R&D expenditures, government initiatives supporting life sciences R&D, the increasing prevalence of chronic and infectious diseases, and growth in initiatives to control environmental pollution. Additionally, the growth in genomics and proteomics, the increasing awareness and growing adoption of personalized medicines, increasing automation and digitalization in the life sciences industry, and the increasing focus on food safety and quality are expected to provide significant opportunities for players operating in the market.
The report offers a competitive landscape based on an extensive assessment of the leading players’ product portfolios and geographic presence and the key growth strategies adopted by them in the last three to four years. In recent years, the life science equipment market witnessed several product launches, product enhancements, product approvals, partnerships, agreements, & collaborations, acquisitions, and expansions.
The key players operating in the life science equipment market are Agilent Technologies, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Waters Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Siemens Healthineers AG (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), and QIAGEN N.V. (Netherlands).
Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=3937 
Growing Awareness and Adoption of Personalized Medicine to Offer Opportunities for Players Operating in the Life Science Equipment Market
Personalized medicine, also known as precision medicine, is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup (also considering genetic changes resulting from a disease) and lifestyle habits. It is an emerging disease treatment and prevention approach that considers individual variability in genes, environment, and lifestyle.
Precision medicine can remove the need for guesswork, variable diagnostic ability, and treatment strategies based on generalized demographics. Moreover, precision medicine enables a more holistic view of an individual patient. Precision medicine for clinical workflows helps facilitate more predictive and preventive care by bringing targeted therapies. There has been an increase in the adoption of personalized medicine in recent years. For instance, according to the Personalized Medicine Coalition, the share of personalized medicine has increased steadily in the total drugs approved in the U.S. by the FDA, from 28% in 2015 to 35% in 2021. The increasing awareness and adoption of personalized medicine are driving the demand for specialized laboratory equipment and technologies that enable precise and accurate genetic and molecular analysis.
Personalized medicine heavily relies on genetic testing, sequencing, analysis of genetic, genomic, and proteomic information, and biomarker identification and validation. This necessitates the use of advanced laboratory equipment, such as DNA sequencers, gene sequencers, PCR machines, real-time PCR systems, next-generation sequencers, mass spectrometers, immunoassay analyzers, and chromatography systems, to accurately derive the necessary results.
The life science equipment market is segmented by Technology [Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzers, PCR, Sequencing, Flow Cytometry, Incubators, Microarray, Centrifuges, Electrophoresis, and Other Equipment], End User [Pharmaceutical and Biotechnology Industry, Academic & Research Institutes, Hospitals and Diagnostic Laboratories, Analytical Testing Laboratories, Agriculture and Food Industry, Forensic Laboratories, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets. (Note: Apart from primary segmentation, Spectroscopy, Microscopy, Chromatography, Lab Automation, Immunoassay Analyzer, PCR, Sequencing, Flow Cytometry, Microarray, Centrifuges, and Electrophoresis have further level segmentation).
Have Specific Research Needs? Request a Customized Report-https://www.meticulousresearch.com/request-customization/cp_id=3937 
Among the technologies included in the report, in 2024, the spectroscopy segment is expected to account for the largest share of 22% of the life science equipment market. The spectroscopy segment is further sub-segmented into molecular spectroscopy, atomic spectroscopy, mass spectrometry, and software. In 2024, the molecular spectroscopy segment is expected to account for the largest share of the spectroscopy market. Molecular spectroscopy is used to determine the composition of a material in an unknown chemical composition. It is used in various applications across food & beverage, environmental screening, pharmaceutical, and biotech industries. Therefore, the wide range of applications of molecular spectroscopy coupled with the growth of the life sciences industry, especially the pharmaceutical and biotech sectors, contribute to the large market share of this segment.
Among the end users included in the report, in 2024, the pharmaceutical and biotechnology industry segment is expected to account for the largest share of 32% of the life science equipment market. The largest share is contributed by several factors, including the increased demand for new drugs and therapies leading to extensive research and development activities, the need for technologically advanced equipment in the pharmaceutical and biotech industries, the rise in funding and investments in the pharmaceutical and biotech industry, and increased healthcare expenditure.
Among the geographies included in the report, in 2024, North America is expected to account for the largest share of 41% of the life science equipment market. North America’s major market share is attributed to the presence of key players, its well-established life science industry, and substantial spending on R&D activities by pharmaceutical and biotech companies. The U.S. is home to global top-ranking pharmaceutical companies. Companies like Johnson & Johnson, Pfizer, AbbVie Inc., Merck, and Bristol Myers Squibb are headquartered in the U.S. These companies have high R&D expenditure at increasing at a high rate each year. For example, Johnson & Johnson spent USD 14.7 billion on research and development in 2021, with a 21% increase over 2020.
Brows In-depth Report- https://www.meticulousresearch.com/product/life-science-equipment-market-3937 
Scope of the Report:
Life Science Equipment Market Assessment—by Technology
SpectroscopyMolecular SpectroscopyUV/Vis SpectroscopyNuclear Magnetic Resonance (NMR)Near-Infrared (NIR) SpectroscopyInfrared (IR) SpectroscopyRaman SpectroscopyPolarimeters and RefractometersFluorescence & Luminescence SpectroscopyOther Molecular Spectroscopy TechnologiesNote: Other molecular spectroscopy technologies segment includes Raman spectroscopy, ellipsometry, and color measurement
Mass SpectrometryQuadrupole LC/MSTime of Flight LC/MS (Q-TOF & LC-TOF)Gas Chromatography-Mass Spectrometry (GC/MS)Fourier Transform Mass Spectrometry (FT/MS)Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectroscopy (MALDI-TOF MS)Portable and In-Field Mass SpectroscopyTandem Mass Spectroscopy (MS/MS)Ion Trap Mass Spectroscopy (LC/MS)Atomic SpectroscopyAtomic Absorbance Spectroscopy (AAS)X-Ray Fluorescence (XRF) SpectroscopyX-Ray Diffraction (XRD) SpectroscopyOther Atomic Spectroscopy TechnologiesNote: Other atomic spectroscopy technologies segment includes inductively coupled plasma (ICP) spectroscopy, glow discharge spectroscopy, and arc/spark optical emission spectroscopy
Spectroscopy SoftwareMicroscopyElectron MicroscopyOptical MicroscopyScanning Probe MicroscopyOther MicroscopyMicroscopy SoftwareChromatographyHigh-Performance Liquid Chromatography (HPLC)Gas Chromatography (GC)Low Pressure Liquid Chromatography (LPLC)Flash ChromatographyThin Layer Chromatography (TLC)Ion ChromatographySupercritical Fluid Chromatography (SFC)Chromatography SoftwareLab AutomationAutomated WorkstationsRobotic SystemsAutomated Storage and Retrieval Systems (ASRS)Lab Automation SoftwareImmunoassay AnalyzersChemiluminescence ImmunoassayFluorescence ImmunoassayRadioimmunoassay (RIA)Colorimetric ImmunoassayOther Immunoassay AnalyzersImmunoassay SoftwarePCRRT-PCRConventional PCRDigital PCRPCR SoftwareSequencingFlow CytometryCell-Based Flow CytometersBead-Based Flow CytometersFlow Cytometry SoftwareIncubatorsMicroarrayDNA MicroarraysProtein MicroarrayTissue ArrayOther MicroarraysMicroarray SoftwareNote: Other microarrays segment includes glycan microarray, carbohydrate microarray, and chemical compounds microarrays
CentrifugesCentrifuges, by TypeDevicesMultipurpose CentrifugesMicrocentrifugesMini centrifugesUltracentrifugesOther CentrifugesCentrifuge AccessoriesCentrifuges, by ModelBenchtop CentrifugesFloor-standing CentrifugesCentrifuges, by ApplicationResearch ApplicationsGenomicsMicrobiologyCellomics ProteomicsClinical ApplicationsDiagnosticsBlood Processing and ScreeningOther ApplicationsElectrophoresisGel ElectrophoresisCapillary ElectrophoresisGel Documentation Systems and SoftwareOther EquipmentNote: Other equipment segment includes autoclaves, stirrers & shakers, mixers, baths, hot plates, ovens & furnaces, and balances
Life Science Equipment Market Assessment —by End User
Pharmaceutical and Biotechnology IndustryAcademic & Research InstitutesHospitals and Diagnostic LaboratoriesAnalytical Testing LaboratoriesAgriculture and Food IndustryForensic LaboratoriesOther End UsersNote: Other end users include blood banks and industries, such as cosmetics, chemicals, oil & gas, electronics & semiconductors, automotive, aerospace, ceramics, plastics, rubber, and paints & coatings
Life Science Equipment Market Assessment —by Geography
North AmericaU.S.CanadaEuropeGermanyU.K.FranceItalySpainSwitzerlandRest of Europe (RoE)Asia-Pacific (APAC)ChinaJapanIndiaSouth KoreaRest of APAC (RoAPAC)Latin AmericaBrazilMexicoRest of LATAM (RoLATAM)Middle East & AfricaSaudi ArabiaUAERest of Middle East & Africa (RoMEA)Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/26911858 
Related Reports:
Genomics Market by Offering (Systems, Consumables, Software, Services), Technology (Sequencing, Microarray, PCR), Application (Diagnostics, Life Science Research), End User (Pharmaceutical Companies, Hospitals, Academic Institutes, CRO) – Global Forecast to 2030
NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) – Global Forecast to 2029
Liquid Handling Systems Market by Type (Automated, Electronic, Manual), Product (Pipette, Consumables, Burette, Software, Microplate), Application (Drug Discovery, Cancer & Genomics, Clinical), End User (Hospital, Diagnostic Lab) – Global Forecast to 2029
High-Performance Liquid Chromatography (HPLC) Market by Product (Instruments [Systems, Detectors], Consumables [Columns, Tubes], Accessories, Software), Application (Forensics, Diagnostics), End User (Research, Pharmaceuticals) – Global Forecast to 2030
Next Generation Sequencing Market by Type (Consumables, NGS Platform, Software), Sequencing Type (Whole Genome, Targeted), Technology (Sequencing by Synthesis, Sequencing by Ligation), Application (Clinical, Research), End User – Global Forecasts to 2030
Chromatography Reagents Market by Type (GC, LC, TLC), Product (Solvents, Buffers, Reagents), Separation (Adsorption, Partition, Affinity), Application (Pharma, Forensic, Environmental, Cosmeceuticals, Diagnostics, QC), End User – Global Forecast to 2030
Related Blogs:
Top 10 Companies in Life Science Equipment Market
Life Science Equipment: The Role of Various Technologies
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected] Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/348/life-science-equipment-market-2031
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/life-science-equipment-market-to-be-worth-97-96-billion-by-2031—exclusive-report-by-meticulous-research-302150104.html

Continue Reading

Trending